Naughton G, Mansbridge J, Gentzkow G, et al.
Artificial organs. Date of publication 1997 Nov 1;volume 21(11):1203-10.
1. Artif Organs. 1997 Nov;21(11):1203-10.
A metabolically active human dermal replacement for the treatment of diabetic
foot ulcers.
Naughton G(1), Mansbridge J, Gentzkow G.
Author information:
(1)Advanced Tissue Sciences, Inc., La Jolla, California 92037, U.S.A.
Tissue engineering, the science of growing living human tissues for
transplantation, promises to revolutionize aspects of medical care. Ulcers of the
skin of the feet of diabetic patients are a serious health problem and a major
cause of amputations. Dermagraft, a tissue-engineered, living human dermal
tissue, which provides normal growth factors and matrix proteins, has been
implanted to replace a patients' destroyed dermises and heal these ulcers.
Large-scale clinical studies and in vitro experiments have demonstrated the
importance of controlling specific product parameters, especially the metabolic
activity of the tissue, to provide, upon implantation into the wound bed, a
living tissue that facilitates healing. Implanting tissue within a defined
therapeutic range of metabolic activity dramatically improves healing of diabetic
foot ulcers, with significantly more ulcers healed completely in a shorter time.
In this new, rapidly moving science, such elucidation of the mechanism of action
is vital to ensure that tissues will provide their intended benefit.
PMID: 9384327 [Indexed for MEDLINE]
